BRIEF-Madrigal Pharmaceuticals Q3 EPS USD -5.08

Reuters
Nov 04
BRIEF-Madrigal Pharmaceuticals Q3 EPS USD -5.08

Nov 04 (Reuters) - Madrigal Pharmaceuticals Q3 net income USD -114.19 million.

  • Q3 operating expenses USD 401.243 million
  • Q3 operating income USD -113.975 million
  • Q3 product revenue USD 287.268 million

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10